分子肿瘤委员会：实现精准肿瘤治疗。
Molecular Tumor Boards: Realizing Precision Oncology Therapy.
机构信息
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Center for Personalized Cancer Therapy and Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA.
出版信息
Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14.
Abstract
Technological advances in high-throughput next-generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene- and immune-targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.
摘要
高通量下一代测序（NGS）技术的进步以及计算过程的进步带来了基因组医学时代的曙光。NGS 实现了恶性肿瘤的分子特征分析，并促进了基因和免疫靶向治疗的发展和批准，这两者都影响了突变组。该技术的临床应用、新型靶向药物的批准以及分子肿瘤委员会的建立使精准肿瘤学成为现实。
相似文献
1
Molecular Tumor Boards: Realizing Precision Oncology Therapy.
Clin Pharmacol Ther. 2018 Feb;103(2):206-209. doi: 10.1002/cpt.920. Epub 2017 Nov 14.
2
Molecular Tumor Boards in Clinical Practice.
Trends Cancer. 2020 Sep;6(9):738-744. doi: 10.1016/j.trecan.2020.05.008. Epub 2020 Jun 6.
3
Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1179-1181. doi: 10.1080/17474124.2018.1535897. Epub 2018 Oct 17.
4
Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
JAMA Oncol. 2016 Jan;2(1):13-4. doi: 10.1001/jamaoncol.2015.4503.
5
Giving Up on Precision Oncology? Not So Fast!
Clin Transl Sci. 2017 May;10(3):128-129. doi: 10.1111/cts.12457. Epub 2017 Feb 21.
6
Implementing Clinical Prediction Models: Pushing the Needle Towards Precision Pharmacotherapy.
Clin Pharmacol Ther. 2018 Feb;103(2):180-183. doi: 10.1002/cpt.752. Epub 2017 Jul 19.
7
Personalized Medicine: Genomics Trials in Oncology.
Trans Am Clin Climatol Assoc. 2015;126:133-43.
8
Delivering on the promise of precision cancer medicine.
Genome Med. 2016 Oct 25;8(1):110. doi: 10.1186/s13073-016-0373-1.
9
Precision medicine: In need of guidance and surveillance.
World J Gastroenterol. 2017 Jul 28;23(28):5045-5050. doi: 10.3748/wjg.v23.i28.5045.
10
Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.
Annu Rev Med. 2017 Jan 14;68:113-125. doi: 10.1146/annurev-med-102115-021556. Epub 2016 Nov 2.
引用本文的文献
1
Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers.
Mol Syst Biol. 2025 Jun 9. doi: 10.1038/s44320-025-00125-1.
2
Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy.
iScience. 2024 Jul 5;27(8):110465. doi: 10.1016/j.isci.2024.110465. eCollection 2024 Aug 16.
3
How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.
Health Sci Rep. 2023 Jun 22;6(6):e1349. doi: 10.1002/hsr2.1349. eCollection 2023 Jun.
4
Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards.
SN Comput Sci. 2023;4(4):358. doi: 10.1007/s42979-023-01771-8. Epub 2023 Apr 27.
5
Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Hematol Rep. 2023 Apr 4;15(2):244-255. doi: 10.3390/hematolrep15020025.
6
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy.
NPJ Precis Oncol. 2022 Sep 22;6(1):67. doi: 10.1038/s41698-022-00309-0.
7
Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.
Clin Oncol Case Rep. 2022 Jan;5(1). Epub 2021 Dec 15.
8
Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.
Mol Oncol. 2022 Jul;16(13):2575-2584. doi: 10.1002/1878-0261.13202. Epub 2022 Apr 8.
9
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
Cancer Treat Rev. 2022 Mar;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub 2022 Jan 5.
10
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
JCO Precis Oncol. 2022 Jan;6:e2000508. doi: 10.1200/PO.20.00508.
本文引用的文献
1
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26.
2
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Cancer Res. 2016 Jul 1;76(13):3690-701. doi: 10.1158/0008-5472.CAN-15-3043. Epub 2016 May 18.
3
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.
4
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.
5
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5.
Zotero 插件